drugset / Trial / NCT07283731
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS
Timeline
- Start
- 2026-06-02
- Primary completion
- 2028-11-01
- Completion
- 2030-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Zanzalintinib | Small molecule | — | Oral |